FENC
Fennec Pharmaceuticals Inc
10.40$
+0.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | – | +9.3% | +98.3% | +95.9% | +49.4% | +160.7% | -71.4% | -4.0% | +13.6% | +10.4% | +10.3% | +29.1% | +10.6% | +9.7% | +18.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +14.3% | +700.0% | +34.4% | +10.5% | +55.8% | +123.6% | +106.9% | -19.7% | +10.5% | +123.2% | -50.7% | -44.2% | +159.2% | -31.7% | +167.3% | -67.7% | +26.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +3.1% | +100.8% | +94.6% | +46.3% | +174.3% | -73.2% | -15.6% | +29.2% | +15.5% | +3.7% | +35.9% | +1.8% | +21.0% | +18.0% | – | |
| – | +55.4% | +29.3% | +48.0% | +47.7% | +80.1% | -22.2% | +15.8% | +125.3% | -4.2% | -3.0% | +17.8% | -59.6% | +47.4% | +18.9% | -19.5% | +22.0% | -10.6% | +97.5% | -66.9% | +55.3% | -57.9% | +174.8% | -21.3% | -25.2% | -86.2% | -96.6% | +100.0% | +50.0% | +166.7% | -90.6% | +5,133.3% | -38.2% | -48.5% | +88.0% | +13.8% | -72.9% | -31.0% | +145.0% | +140.8% | – | |
| – | +115.0% | -43.8% | +109.9% | +47.8% | -3.8% | -32.4% | +69.4% | -43.8% | +31.6% | -27.0% | +181.9% | -62.4% | +132.3% | -1.6% | +52.5% | +20.6% | -48.9% | +9.3% | +24.5% | -6.1% | +25.7% | -42.8% | +83.9% | +81.9% | -33.6% | -7.8% | +27.3% | -30.8% | +83.1% | -15.7% | +16.9% | -10.8% | -31.4% | +39.8% | +18.6% | -2.9% | +25.0% | -62.3% | +45.6% | – | |
| – | +103.2% | -32.7% | +91.8% | +47.8% | +15.1% | -28.8% | +48.8% | +6.9% | +9.0% | -13.7% | +79.6% | -61.3% | +96.1% | +5.0% | +26.3% | +20.9% | -40.0% | +40.0% | -20.4% | +6.5% | +0.8% | -15.7% | +41.3% | +57.7% | -2.9% | -10.7% | +14.5% | -8.2% | +50.9% | +2.0% | +5.5% | -7.3% | -24.2% | +12.0% | +24.1% | +5.1% | +21.6% | +0.4% | +5.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -136.7% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | +41.7% | +0.0% | +70.6% | – | – | – | – | – | +125.0% | +506.9% | +13.5% | -6.5% | -2.6% | +110.6% | +585.1% | -2.1% | +14.0% | -5.9% | +6.9% | +13.0% | +3.2% | -3.9% | -5.8% | -37.6% | +2.3% | -5.0% | -47.4% | -97.7% | -57.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -143.3% | – | – | – | – | – | – | – | +902.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -104.1% | – | – | +34.8% | +48.4% | -115.2% | – | +1,216.9% | +69.0% | -47.8% | +3.8% | -100.0% | -72,300,100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -143.3% | – | – | – | – | – | – | – | +881.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -130.7% | – | – | – | – | – | – | – | +653.4% | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.